申请人:Tanabe Seiyaku Co., Ltd.
公开号:US04625032A1
公开(公告)日:1986-11-25
Tetrahydro-.beta.-carboline derivative of the formula: ##STR1## wherein R.sup.2 is lower alkyl, and either (A) R.sup.1 is hydroxymethyl or carboxy, R.sup.3 and R.sup.4 are both hydrogen, and X is halogen, lower alkyl, lower alkoxy, hydroxy or benzyloxy; or (B) R.sup.1 is hydrogen, carboxy-lower alkyl or a group of the formula: --CH.sub.2 OY, Y is lower alkyl, lower alkanoyl or an oxygen-containing monocyclic heterocyclic group, R.sup.3 is hydrogen, hydroxy-lower alkyl or carboxy, R.sup.4 is hydrogen or hydroxy-lower alkyl, and X is hydrogen, or a salt thereof, which has excellent activities for alleviating, curing and preventing hepatic damages and is useful as a therapeutic or prophylactic agent for hepatic diseases.
Tetrahydro-.beta.-carboline衍生物的化学式:##STR1##其中R.sup.2为低级烷基,且(A)R.sup.1为羟甲基或羧基,R.sup.3和R.sup.4均为氢,X为卤素,低级烷基,低级烷氧基,羟基或苄氧基;或(B)R.sup.1为氢,羧基-低级烷基或式:--CH.sub.2 OY的基团,其中Y为低级烷基,低级烷酰基或含氧的单环杂环基团,R.sup.3为氢,羟基-低级烷基或羧基,R.sup.4为氢或羟基-低级烷基,X为氢,或其盐。该化合物具有优异的缓解、治疗和预防肝脏损伤的活性,可作为治疗或预防肝脏疾病的治疗药物或预防药物。